Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$20.57 CAD
Change Today 0.00 / 0.00%
Volume 0.0
TR On Other Exchanges
Symbol
Exchange
NASDAQ CM
Toronto
Berlin
As of 4:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

trillium therapeutics inc (TR) Snapshot

Open
C$20.11
Previous Close
C$20.57
Day High
C$20.76
Day Low
C$20.10
52 Week High
04/13/15 - C$37.27
52 Week Low
10/17/14 - C$6.15
Market Cap
151.0M
Average Volume 10 Days
8.7K
EPS TTM
C$-3.35
Shares Outstanding
7.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TRILLIUM THERAPEUTICS INC (TR)

Related News

No related news articles were found.

trillium therapeutics inc (TR) Related Businessweek News

No Related Businessweek News Found

trillium therapeutics inc (TR) Details

Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. Its primary program is SIRPaFc, an antibody-like fusion protein, which blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system. The company also develops CD200 mAb, a human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by various hematopoietic and solid tumors. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada.

18 Employees
Last Reported Date: 04/1/15
Founded in 2004

trillium therapeutics inc (TR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$390.0K
Chief Financial Officer
Total Annual Compensation: C$218.8K
Chief Development Officer
Total Annual Compensation: C$205.0K
Chief Scientific Officer
Total Annual Compensation: C$270.0K
Compensation as of Fiscal Year 2014.

trillium therapeutics inc (TR) Key Developments

Trillium Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Trillium Therapeutics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss and comprehensive loss was CAD 5,568,564 against CAD 4,100,371 a year ago. Basic and diluted loss per common share was CAD 0.80 against CAD 0.99 a year ago. For the six months, the company reported net loss and comprehensive loss was CAD 10,238,877 against CAD 6,140,431 a year ago. Basic and diluted loss per common share was CAD 0.80 against CAD 0.99 a year ago. Cash used in operating activities was CAD 9,403,113 against CAD 3,207,089 a year ago. The increase was mainly due to an increase in research and development expenses relating to the SIRPaFc program of CAD 4,269,123 compared to the prior year. Purchase of property and equipment was CAD 99,344 against CAD 139,997 a year ago.

Trillium Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for First Third Quarter Ended March 31, 2015

Trillium Therapeutics Inc. reported unaudited consolidated earnings results for first third quarter ended March 31, 2015. For the quarter, the company reported net loss and comprehensive loss of CAD 4,670,313 or CAD 0.98 per basic and diluted common share compared to CAD 2,040,060 or CAD 0.50 per basic and diluted common share a year ago. Finance loss was CAD 70,741 compared to CAD 108,592 a year ago. Cash used in operating activities was CAD 4,612,249 compared to CAD 1,509,541 a year ago. Purchase of property and equipment was CAD 82,814 compared to CAD 10,091 a year ago.

Trillium Therapeutics Inc., Annual General Meeting, May 27, 2015

Trillium Therapeutics Inc., Annual General Meeting, May 27, 2015., at 15:00 US Eastern Standard Time. Location: at the offices of the Corporation at 96 Skyway Avenue. Agenda: To receive the audited consolidated financial statements of the Corporation for the year ended December 31, 2014, together with the auditors' report thereon; to elect directors of the Corporation for the ensuing year; to reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors; and to transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TR:CN C$20.57 CAD 0.00

TR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TR.
View Industry Companies
 

Industry Analysis

TR

Industry Average

Valuation TR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRILLIUM THERAPEUTICS INC, please visit www.trilliumtherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.